Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells Abstract #1506

Introduction: PRRT can deliver radiation doses of up to 250 Gy to the tumors. Nevertheless, complete remission is extremely rare, compared to similar radiotherapies for thyroid cancer and non-Hodgkin lymphoma.
Aim(s): One hypothesis potentially explaining the discrepancies between expected result and observed outcome of PRRT might be that somatostatin analogs induce a G1 arrest in NET cells, thereby rendering them radioresistant. Other medical therapeutics like mTOR inhibitors may also contribute to radiosensitivity towards PRRT.
Materials and methods: To investigate this, NET cell lines were incubated with or without agonists and exposed to different radiation doses from a 137Cs source between 0 and 50 Gy. Cells were harvested at distinct timepoints, stained with propidium iodide and the cell cycle distribution was assessed by FACS analysis. Proliferation, vitality and mitochondrial activity were assessed using cell counting, clonogenic assay and Alamar Blue assay, respectively.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr. Carsten Grötzinger
Keywords: PRRT

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2291 Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells
Introduction: Neuroendocrine tumors (NETs) express somatostatin receptors that are currently utilized for diagnostic and therapeutic approaches. For peptide receptor radionuclide therapy (PRRT), somatostatin analogs are coupled to radionuclides like 90Y or 177Lu, which after injection are bound and taken up specifically by NETs. One hypothesis potentially explaining the discrepancies between expected result and observed outcome of PRRT might be that somatostatin analogs induce a G1 arrest in NET cells, thereby rendering them radioresistant.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Carsten Grötzinger
Keywords: PRRT
#2294 Identification and Validation of the Angiotensin II Receptor Type 1 as a Possible Anti-Cancer Target in Neuroendocrine Tumors
Introduction: Neuroendocrine tumours (NETs) have been found to overexpress somatostatin receptors (SSTRs), which led to the development of somatostatin analogs utilized for diagnostics and therapeutics. However, around 30% of all NETs do not respond to somatostatin based approaches, leading to an interest to find and characterize alternative cell surface targets.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Carsten Grötzinger
#1808 Lanreotide Autogel/Depot (LAN) in Combination with Peptide Receptor Radionuclide Therapy (PRRT) in Progressive Digestive and Lung Neuroendocrine Tumours (NETs): Design of the PRELUDE Study
Introduction: PRRT has potential to control progressive NETs and has been used in combination with somatostatin analogues such as LAN.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Vikas Prasad
Keywords: PRRT, lanreotide
#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs
Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Budiawan H, Ali S, Hoersch D, ...
#1577 Peritoneal Carcinomatosis in Digestive Neuroendocrine Neoplasms: Complications and Response to Therapy
Introduction: Peritoneal carcinomatosis (PC) is present in 10-30% of digestive neuroendocrine neoplasms (DNENs), affecting prognosis and quality of life with recurrent abdominal pain and bowel obstruction
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD, PhD Elettra Merola
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.